Scarica l'app Stockscreener
6.227
3.27%
0.197
Precedente Chiudi:
$6.03
Aprire:
$6.05
Volume 24 ore:
17,758
Relative Volume:
0.24
Capitalizzazione di mercato:
$100.75M
Reddito:
-
Utile/perdita netta:
$-12.36M
Rapporto P/E:
-4.6943
EPS:
-1.3265
Flusso di cassa netto:
$-11.39M
1 W Prestazione:
-8.56%
1M Prestazione:
-24.70%
6M Prestazione:
-24.98%
1 anno Prestazione:
+25.54%
Intervallo 1D:
$6.05
$6.44
Intervallo di 1 settimana:
$5.90
$6.9109
Portata 52W:
$4.75
$10.69
Coya Therapeutics Inc Stock (COYA) Company Profile
Nome
Coya Therapeutics Inc
Settore
Industria
Telefono
650.739.3939
Indirizzo
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Confronta COYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| COYA | 6.15 | 100.75M | 0 | -12.36M | -11.39M | -1.3265 |
| VRTX | 450.39 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.43 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.94 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.90 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Coya Therapeutics Inc Borsa (COYA) Ultime notizie
Coya Therapeutics sets sights on neurodegenerative trials in 2025 - Investing.com India
Coya Therapeutics Advances $700M ALS Program, Sets Key 2025 Clinical Milestones | COYA Stock News - StockTitan
Trend Tracker for (COYA) - Stock Traders Daily
Insider Buying: CFO David Snyder Acquires Shares of Coya Therape - GuruFocus.com
Coya therapeutics CFO David Snyder buys $12,934 in stock - Investing.com
HC Wainwright Has Positive Forecast for COYA FY2024 Earnings - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Announces Earnings Results - MarketBeat
Meet 5 of the fastest-growing scaleup companies in Houston - InnovationMap
INNOVATIONMAP EMAILS ARE AWESOME - InnovationMap
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Coya Therapeutics Reports Q3 2024 Highlights and Progress - TipRanks
Coya Therapeutics board member resigns due to new job policy By Investing.com - Investing.com Canada
Coya Therapeutics Advances Pipeline for Neurodegenerative Diseases - TipRanks
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results - The Bakersfield Californian
Coya Therapeutics board member resigns due to new job policy - Investing.com India
Long Term Trading Analysis for (COYA) - Stock Traders Daily
Arun Swaminathan assumes new role as chief executive officer of Coya Therapeutics - pharmabiz.com
Coya Therapeutics appoints new CEO amid Alzheimer's trial progress By Investing.com - Investing.com South Africa
Coya Therapeutics, Inc. (NASDAQ:COYA) Sees Significant Increase in Short Interest - MarketBeat
Coya Therapeutics appoints new CEO amid Alzheimer's trial progress - Investing.com
Coya Therapeutics Promotes Arun Swaminathan, Ph.D. to Chief Executive Officer - citybiz
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer - StockTitan
Coya Therapeutics announces executive changes - Investing.com India
Coya Therapeutics Announces Leadership Change and New CEO - TipRanks
Coya Therapeutics announces executive changes By Investing.com - Investing.com UK
Coya Therapeutics On Developing A Combination Biologic - BioProcess Online
Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off (NASDAQ:COYA) - Seeking Alpha
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results - Yahoo Finance
Coya Therapeutics reports promising Alzheimer's trial results By Investing.com - Investing.com South Africa
See the Impacts of Waco’s Walk to End Alzheimer’s - AOL
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Yahoo Finance
Coya stock tumbles 23% on mixed results from Alzheimer's study - MSN
Coya stock tumbles 23% on mixed results from Alzheimer's study (NASDAQ:COYA) - Seeking Alpha
Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth - Simply Wall St
Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial - Reuters
Coya Therapeutics reports promising Alzheimer's trial results - Investing.com
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease - StockTitan
When (COYA) Moves Investors should Listen - Stock Traders Daily
Coya Therapeutics secures $10 million in private placement By Investing.com - Investing.com Australia
Coya Therapeutics Announces $10.0 Million Private Placement - citybiz
Coya Therapeutics Shares Rise 9% After $10 Million Private Placement - MarketWatch
Coya Therapeutics secures $10 million in private placement - Investing.com
Coya Therapeutics Announces $10M Private Placement to Advance Pipeline - TipRanks
Tips for preventing or delaying dementia - AOL
Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts - Seeking Alpha
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100 - citybiz
Exosomes Pipeline Dynamics 2024: FDA Approvals, Therapeutic - openPR
Coya Therapeutics Inc Azioni (COYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Coya Therapeutics Inc Azioni (COYA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):